Boundless Bio, Inc.(US:BOLD)2026-03-09 11:05Financial Performance - Boundless Bio reported a net loss of $12.9 million for Q4 2025, compared to a net loss of $16.4 million in Q4 2024, and a full-year net loss of $58.2 million for 2025, down from $65.4 million in 2024[10]. - General and Administrative (G&A) expenses for Q4 2025 were $4.2 million, compared to $5.0 million in Q4 2024, while full-year G&A expenses were $18.7 million, slightly up from $18.0 million in 2024[10]. - Total operating expenses for Q4 2025 were $14.0 million, down from $18.3 million in Q4 2024, and full-year operating expenses were $63.6 million, compared to $73.3 million in 2024[10]. - Boundless Bio's accumulated deficit reached $259.7 million as of December 31, 2025, compared to $201.5 million in 2024[14]. - Total assets decreased to $157.1 million in 2025 from $206.4 million in 2024, while total liabilities increased slightly to $58.4 million from $55.8 million[14]. Research and Development - Research and Development (R&D) expenses for Q4 2025 were $9.8 million, a decrease from $13.3 million in Q4 2024, while full-year R&D expenses totaled $44.8 million, down from $55.3 million in 2024[10]. - Boundless Bio's KOMODO-1 trial for BBI-940, a novel oral Kinesin degrader, is currently open for enrollment, targeting patients with specific types of breast cancer[5]. - The company plans to deliver initial safety and efficacy clinical proof-of-concept data from the KOMODO-1 trial within its existing cash runway timeline[5]. - The company has ceased enrollment in the Phase 1/2 POTENTIATE trial to prioritize the BBI-940 program based on market considerations and available clinical data[4]. Cash Position - The company had cash, cash equivalents, and short-term investments of $107.6 million as of December 31, 2025, which is expected to fund operations into the second half of 2028[10].